Form 4: Corcept Therapeutics CDO Sells Shares After Option Exercise

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold 20,000 shares of common stock.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), exercised 20,000 stock options at an exercise price of $21.65 per share.
• Concurrently, Guyer sold 20,000 shares of common stock at a weighted average price of $40.8667 per share.
• The transactions were executed on February 3, 2026, under a Rule 10b5-1 trading plan adopted on November 27, 2024.
• Following these transactions, Guyer beneficially owns 1,235 shares of common stock and 230,000 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale might be seen negatively, it was pre-planned and the insider retains a significant option stake, suggesting no immediate change in company fundamentals.

Positives

• The sale price of $40.8667 per share is significantly higher than the option exercise price of $21.65, indicating a substantial gain for the reporting person.
• The transaction was conducted under a pre-arranged 10b5-1 plan, suggesting a planned and not reactive sale.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, as it reduces their direct equity stake.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under pre-arranged 10b5-1 plans, are common and do not necessarily signal a negative outlook for the company. Such plans are often used by executives for personal financial planning and diversification.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Development Officer could be interpreted in various ways, but given it's a 10b5-1 plan, it's likely for personal financial planning rather than a reflection on company performance.

Key Dates

Recommendation

The filing details a routine insider transaction (exercise and sale) executed under a pre-planned 10b5-1 program. This type of transaction is common for executive compensation and personal financial management and does not typically indicate a change in the company's fundamental outlook. The insider retains a substantial number of options, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to warrant a change in investment thesis.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, Share Sale, William Guyer, Chief Development Officer, 10b5-1 Plan